Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neuroblastoma 9Melanoma 4Ganglioneuroblastoma 4Triple Negative Breast Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Transplant-Related Hematologic Malignancy 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Alveolar Soft Part 1Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

sargramostim 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Transplant-Related Hematologic Malignancy × sargramostim × 1 year × Clear all
NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

Northside Hospital, Inc.

Phase 2 Recruiting
38 enrolled

Transplant-Related Hematologic Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡